Literature DB >> 17266092

Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group.

Bernard Ravina1, Karen Marder, Hubert H Fernandez, Joseph H Friedman, William McDonald, Diane Murphy, Dag Aarsland, Debra Babcock, Jefferey Cummings, Jean Endicott, Stewart Factor, Wendy Galpern, Andrew Lees, Laura Marsh, Mark Stacy, Katrina Gwinn-Hardy, Valerie Voon, Christopher Goetz.   

Abstract

There are no standardized diagnostic criteria for psychosis associated with Parkinson's disease (PDPsy). As part of an NIH sponsored workshop, we reviewed the existing literature on PDPsy to provide criteria that distinguish PDPsy from other causes of psychosis. Based on these data, we propose provisional criteria for PDPsy in the style of the Diagnostic and Statistical Manual of Mental Disorders IV-TR. PDPsy has a well-characterized temporal and clinical profile of hallucinations and delusions, which is different than the pattern seen in other psychotic disorders such as substance induced psychosis or schizophrenia. PDPsy is associated with a poor prognosis of chronic psychosis, nursing home placement, and death. Medications used to treat Parkinson's disease (PD) contribute to PDPsy but may not be sufficient or necessary contributors to PDPsy. PDPsy is associated with Lewy bodies pathology, imbalances of monoaminergic neurotransmitters, and visuospatial processing deficits. These findings suggest that PDPsy may result from progression of the disease process underlying PD, rather than a comorbid psychiatric disorder or drug intoxication. PDPsy is not adequately described by existing criteria for psychotic disorders. We established provisional diagnostic criteria that define a constellation of clinical features not shared by other psychotic syndromes. The criteria are inclusive and contain descriptions of the full range of characteristic symptoms, chronology of onset, duration of symptoms, exclusionary diagnoses, and associated features such as dementia. These criteria require validation and may be refined, but form a starting point for studies of the epidemiology and pathophysiology of PDPsy, and are a potential indication for therapy development.

Entities:  

Mesh:

Year:  2007        PMID: 17266092     DOI: 10.1002/mds.21382

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  107 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

2.  The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria.

Authors:  Gilles Fénelon; Thierry Soulas; Franck Zenasni; Laurent Cleret de Langavant
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

Review 3.  Toward a neurobiology of delusions.

Authors:  P R Corlett; J R Taylor; X-J Wang; P C Fletcher; J H Krystal
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

Review 4.  Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.

Authors:  Daniel Weintraub; Howard I Hurtig
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

Review 5.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

6.  Delusions in Parkinson's Disease: A Systematic Review of Published Cases.

Authors:  Nicola Warren; Cullen O'Gorman; Zena Hume; Steve Kisely; Dan Siskind
Journal:  Neuropsychol Rev       Date:  2018-08-02       Impact factor: 7.444

7.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

8.  Treatment of Parkinson's disease psychosis.

Authors:  Kevin J Black
Journal:  Med Int Rev       Date:  2018-02-03

Review 9.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

10.  Treatment of psychosis and dementia in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden
Journal:  Curr Treat Options Neurol       Date:  2014-03       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.